Prof. Hans Clevers

Prof. Hans Clevers is one of the most influential biomedical scientists of the past three decades, internationally recognized for discoveries that have fundamentally changed our understanding of how the intestinal epithelium renews itself, how this process goes awry in cancer, and how the resulting knowledge can be translated into new diagnostic and therapeutic tools for patients. Trained as both a physician and a molecular biologist, he bridges the worlds of basic science and clinical medicine in a way that is exceptionally rare even among top academic doctors.

Prof. Clevers' scientific career has been built primarily at the Hubrecht Institute in Utrecht—one of Europe's foremost institutes for developmental biology and stem cell research, affiliated with the Royal Netherlands Academy of Arts and Sciences—where he led research groups for over two decades. More recently, he has extended his activities to the Princess Máxima Center for Pediatric Oncology in Utrecht, the Netherlands' national center for childhood cancer, where his organoid technology is being applied to help predict drug responses for individual children with cancer.

His most celebrated scientific achievement is the development of intestinal organoids: miniature, self-organizing three-dimensional models of the intestinal epithelium grown in the laboratory from a patient's own stem cells. These organoids faithfully recapitulate the architecture and function of the living gut and can be used to test how a specific patient's tissue responds to candidate drugs—a direct application of precision medicine. For cystic fibrosis, this technology has already transformed patient care: organoids grown from rectal biopsy cells predict which patients with CF will respond to CFTR modulators such as ivacaftor and lumacaftor, enabling individualized drug selection.

As a clinician, Prof. Clevers consults on complex pediatric cases involving intestinal disorders, hereditary cancer syndromes, and conditions where organoid-based drug testing can guide treatment decisions, working within multidisciplinary teams at the Princess Máxima Center.

Prof. Clevers obtained his MD from Utrecht University and subsequently completed his PhD in immunology, also at Utrecht, studying T-cell receptor biology. Recognizing that the most fundamental advances in medicine require mastery of molecular biology, he undertook postdoctoral research training at the Whitehead Institute for Biomedical Research at MIT in Boston—one of the world's foremost molecular biology institutions—where he trained with Nobel Prize-caliber scientists and developed the molecular genetic skills that would underpin his later work on Wnt signaling and stem cells. Returning to the Netherlands, he built his independent research program at Utrecht University and the Hubrecht Institute, rising to become its director. He is a Foreign Member of the Royal Society (FRS) of London, one of the highest honors in science, and a full member of EMBO and KNAW. He has held visiting professorships and honorary doctorates at universities across Europe, North America, and Asia.

Prof. Clevers' clinical work is defined by his unique ability to apply organoid technology to real patient care decisions. In the context of cystic fibrosis, he works with CF centers to grow patient-derived intestinal organoids and use them to test the efficacy of specific CFTR modulator drugs before prescribing them—a paradigm now incorporated into Dutch clinical practice guidelines for CF. For pediatric oncology at the Princess Máxima Center, he contributes to molecular tumor characterization and the use of organoid models to predict tumor drug sensitivity, helping oncologists select chemotherapy regimens for children with rare or refractory cancers.

For hereditary intestinal cancer syndromes—including familial adenomatous polyposis and Lynch syndrome in pediatric patients—he provides genetic counseling and helps coordinate surveillance strategies that draw on the latest understanding of Wnt pathway biology. In pediatric IBD, he applies his deep understanding of intestinal epithelial biology and inflammatory pathways to guide both conventional therapies (aminosalicylates, steroids, immunomodulators, biologics) and experimental approaches. His pediatric endoscopy practice supports tissue acquisition for organoid establishment and diagnostic evaluation of mucosal disease.

Prof. Clevers has published over 500 peer-reviewed papers in the world's most prestigious scientific journals, including Cell, Nature, Science, the New England Journal of Medicine, and Nature Medicine, making him one of the most cited biomedical researchers alive. His landmark 2009 Nature paper describing the first successful growth of intestinal organoids from Lgr5+ stem cells is among the most cited papers in biology of the past two decades and spawned an entire new field of organoid science that now extends to liver, pancreas, lung, kidney, brain, and tumor organoids.

His work on Wnt signaling—identifying TCF4 as a key transcription factor in the Wnt pathway and showing its central role in intestinal crypt maintenance and colorectal cancer—earned him the inaugural Heineken Prize for Medicine and the Breakthrough Prize in Life Sciences. His research group at the Hubrecht Institute continues to publish landmark studies on stem cell biology, organoid technology, and its applications to drug discovery and personalized medicine. He has been principal investigator on multiple ERC Advanced Grants and NWO Spinoza grants.

Prof. Clevers sees patients in a specialized clinical capacity at the Princess Máxima Center for Pediatric Oncology in Utrecht, which is the national referral center for childhood cancer in the Netherlands and regularly receives patients from other European countries and internationally. The center has an international patient coordination service with multilingual support. Prof. Clevers consults in Dutch and English. For families of children with rare cancers or complex intestinal conditions where organoid-based drug testing may be applicable, he is one of the very few clinician-scientists worldwide who can both order and interpret these tests in a direct patient care context. EU patients may access care under EU cross-border provisions; non-EU families are accommodated on a private basis with cost and logistics support from the center's international office. Video consultations can facilitate initial case review before a family commits to travel.

Prof. Clevers' awards represent the highest honors available in international science and medicine. He is a recipient of the Spinoza Prize—the Netherlands' highest science award, awarded by the Netherlands Organisation for Scientific Research (NWO)—which recognizes researchers who rank among the absolute world leaders in their field. He received the Heineken Prize for Medicine, one of the most prestigious Dutch scientific prizes, for his work on Wnt signaling and intestinal stem cells. He received the Breakthrough Prize in Life Sciences—one of the world's richest science prizes, established by Silicon Valley founders—for his revolutionary contributions to organoid biology. He is a Foreign Member of the Royal Society of London (FRS), a Member of EMBO, a Member of KNAW, and has received honorary doctorates from multiple universities. He has received the Dr. Paul Janssen Award for Biomedical Research and the Gairdner Foundation International Award, which is widely regarded as a precursor to the Nobel Prize.